FDA product code GXH: Device, Surgical, Cryogenic
GXH is the FDA product code for device, surgical, cryogenic. It is a Class II device, regulated under 21 CFR 882.4250 and reviewed by the Neurology panel. FDA has cleared 23 510(k) submissions under GXH, 5 in the last five years, from 8 different applicants. The average 510(k) review took 93 days (median 60); 44 days on average over the last three years. FDA has posted 2 recalls for GXH devices.
Classification
| Field | Value |
|---|---|
| Device name | Device, Surgical, Cryogenic |
| Device class | Class II |
| Regulation | 21 CFR 882.4250 |
| Review panel | NE — Neurology |
| Medical specialty | Neurology |
| Premarket route | 510(k) |
| Third-party 510(k) review eligible | Yes |
510(k) clearances per year for GXH
| Year | Clearances | Avg. review days |
|---|---|---|
| 2017 | 1 | 262 |
| 2018 | 3 | 53 |
| 2020 | 1 | 281 |
| 2021 | 1 | 130 |
| 2022 | 1 | 74 |
| 2023 | 1 | 29 |
| 2024 | 2 | 29 |
| 2025 | 1 | 59 |
Compare with all 510(k) review times · Search every GXH clearance
Top GXH applicants
| Applicant | Clearances | Latest |
|---|---|---|
| Myoscience, Inc. | 8 | 2018-02-28 |
| AtriCure, Inc. | 7 | 2025-04-10 |
| Pacira Biosciences, Inc. | 2 | 2024-12-26 |
| Spembly Medical , Ltd. | 2 | 1983-08-12 |
| Pacira Pharmaceuticals, Inc. | 1 | 2021-09-10 |
3 more applicants have GXH clearances. See the full list in Caduvo.
Most recent GXH clearances
| 510(k) | Applicant | Device | Decision date | Review days |
|---|---|---|---|---|
| K250371 | AtriCure, Inc. | cryoICE cryoXT cryoablation probe (cryoXT) | 2025-04-10 | 59 |
| K243677 | Pacira Biosciences, Inc. | iovera° System | 2024-12-26 | 29 |
| K243157 | AtriCure, Inc. | AtriCure cryoICE BOX (ACM) | 2024-10-29 | 29 |
| K233170 | AtriCure, Inc. | cryoICE cryoSPHERE+ Cryoablation Probe (CRYOSP); cryoICE cryoSPHERE+ Cryoablation Probe (CRYOSP-L); cryoICE cryoSPHERE MAX Cryoablation Probe (CRYOSMAX); cryoICE cryoSPHERE MAX Cryoablation Probe (CRYOSMAX-L) | 2023-10-26 | 29 |
| K220656 | Pacira Biosciences, Inc. | iovera System | 2022-05-20 | 74 |
Recalls for GXH devices
2 product recalls in 2 recall events; 0 initiated in the last five years and 0 still open. Most recent: 2015-07-01.
Frequently asked questions
What is FDA product code GXH?
GXH is the FDA product code for device, surgical, cryogenic. It is a Class II device, regulated under 21 CFR 882.4250 and reviewed by the Neurology panel.
What device class is GXH?
Class II, regulation 21 CFR 882.4250. Typical premarket route: 510(k).
How long does a 510(k) take for product code GXH?
Across 23 cleared submissions the average was 93 days from receipt to decision (median 60).
Which companies have the most GXH clearances?
Myoscience, Inc. (8); AtriCure, Inc. (7); Pacira Biosciences, Inc. (2); Spembly Medical , Ltd. (2); Pacira Pharmaceuticals, Inc. (1).
Have GXH devices been recalled?
Yes: 2 product recalls across 2 recall events; the most recent began 2015-07-01.
Next steps
- Run an FDA pathway report with predicate devices for product code GXH
- Run a recall and safety report across every GXH manufacturer
- Watch product code GXH for new clearances and recalls
Compiled by Caduvo from public U.S. FDA records. Applicant names are shown as FDA records them. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA. Not regulatory advice. Report an error. Data and corrections policy.
All Neurology product codes · FDA product code lookup · 510(k) database search · 510(k) review times